Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1027-1036

  Karakhanova, S ^a   Ryschich, E ^a   Mosl, B ^a   Harig, S ^a   Jager D ^a   Schmidt, J ^a,b   Hartwig, W ^c   Werner, J ^c   Bazhin, A V ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b General and Visceral Surgery Center   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CapRI; disease free survival; immunotherapy; interferon a; overall survival; pancreatic carcinoma

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOLOGY; IMMUNOLOGICAL PARAMETERS; K562 CELL LINE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATURAL KILLER CELL; NEUTROPHIL; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT OUTCOME; ADENOCARCINOMA; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOIMMUNOTHERAPY;

EID: 84925298945     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.72     Document Type: Article

References (38)

1. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2): 465-72.
2. Baron S, Finbloom J, Horowitz J, Bekisz J, Morrow A, Zhao T, Fey S, Schmeisser H, Balinsky C, Miyake K, Clark C, Zoon K (2011) Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro. J Interferon Cytokine Res 31(7): 569-73.
3. Baron S, Hernandez J, Bekisz J, Poast J, Goldman N, Clouse K, Fields K, Bacot S, Wang J, Zoon K (2007) Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. J Interferon Cytokine Res 27(2): 157-63.
4. Bazhin AV, Bayry J, Umansky V, Werner J, Karakhanova S (2013) Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology 2(9): e25736.
5. Bazhin AV, Shevchenko I, Umansky V, Werner J, Karakhanova S (2014) Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother 63(1): 59-65.
6. Bellati F, Visconti V, Napoletano C, Antonilli M, Frati L, Panici PB, Nuti M (2009) Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 9(4): 541-65.
7. Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W (2012) A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 118(16): 3984-92.
8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-25.
9. Copier J, Whelan M, Dalgleish A (2006) Biomarkers for the development of cancer vaccines: current status. Mol Diagn Ther 10(6): 337-43.
10. Cress RD, Yin D, Clarke L, Bold R, Holly EA (2006) Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17(4): 403-9.
11. Forster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8(5): 362-71.
12. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1): e26-31.
13. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102(2): 169-78.
14. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-4.
15. Gogas H, Kirkwood JM (2009) Predictors of response to interferon therapy. Curr Opin Oncol 21(2): 138-43.
16. Hadrup S, Donia M, Thor Straten P (2013) Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 6(2): 123-33.
17. Hinoda Y, Ikematsu Y, Horinochi M, Sato S, Yamamoto K, Nakano T, Fukui M, Suehiro Y, Hamanaka Y, Nishikawa Y, Kida H, Waki S, Oka M, Imai K, Yonezawa S (2003) Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 38(12): 1162-6.
18. Jager D, Seil I, Halama N (2011) Predictive immunological markers in oncology. Front Immunol 2: 86.
19. Jimeno A, Hidalgo M (2006) Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 5(4): 787-96.
20. Karakhanova S, Mosl B, Harig S, Ahn K, Fritz J, Schmidt J, Jager D, Werner J, Bazhin AV (2014) Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Int J Mol Sci 15(3): 4104-25.
21. Knaebel HP, Marten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, Herrmann T, Goldschmidt H, Krempien R, Mansmann U, Debus J, Diehl V, Buchler MW (2005) Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol [ISRCTN62866759]. BMC Cancer 5: 37.
22. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5(5): 397-405.
23. Laumbacher B, Gu S, Wank R (2012) Activated monocytes prime naive T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo. Scand J Immunol 75(3): 314-28.
24. Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM (1992) T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 90(2): 235-44.
25. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10): 1073-81.
26. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3): 267-77.
27. Pedroza-Pacheco I, Madrigal A, Saudemont A (2013) Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol 10(3): 222-9.
28. Randolph GJ, Jakubzick C, Qu C (2008) Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 20(1): 52-60.
29. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Frohlich B, Klar E, Buchler MW, Schmidt J (2005) Control of T-cellmediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 11(2 Pt 1): 498-504.
30. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-63.
31. Schmidt J, Abel U, Debus J,Harig S, Hoffmann K, Herrmann T, BartschD,Klein J, Mansmann U, Jager D, Capussotti L, Kunz R, Buchler MW(2012) Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 30(33): 4077-83.
32. Schmidt J, Jager D, Hoffmann K, Buchler MW, Marten A (2007) Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 30(1): 108-15.
33. Simon R (2008) The use of genomics in clinical trial design. Clin Cancer Res 14(19): 5984-93.
34. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69(6): 979-85.
35. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109(2): 416-21.
36. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL (1996) CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153: 47-83.
37. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, MaWW, SalehMN, HarrisM, ReniM, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18): 1691-703.
38. Zabel MD, Weis JH (2001) Cell-specific regulation of the CD21 gene. Int Immunopharmacol 1(3): 483-93.